Latest Biotech & Health Tech
News & Analysis

Novo Nordisk (NVO) just sued Hims & Hers (HIMS) for selling copycat versions of Wegovy. The health-tech war continues and the market answered fast. 

Hims stock slid after the company pulled its $49 GLP-1 pill following an FDA warning that it would rapidly enforce laws against copycat drugs.

Novo Nordisk (NVO) stock can recover. But it won’t look like the last run. The last two weeks reminded everyone that even disruptors can get disrupted.

Novo Nordisk (NVO) stock slides again after Hims & Hers Health (HIMS) rolled out a compounded semaglutide weight loss pill priced to shock the system. 

Health tech giant Eli Lilly (LLY) just told the market what actually matters for its obesity pill launch. Medicare is coming in at the door, day one.

Health tech company AstraZeneca (AZN) just signed a licensing deal worth up to $18.5 billion to access Made-in-China obesity drugs from China’s CSPC Pharmaceutical Group. 

Biotech company Bristol Myers Squibb (BMY) just connected its cancer franchise to Microsoft’s (MSFT) AI radiology stack to spot lung cancer earlier.

The Wegovy pill launch just reminded the market that health-tech company Novo Nordisk (NVO) still runs the obesity drug game. Early prescriptions for the Wegovy pill hit hard and Wall Street noticed.

2026 is shaping up to be the year of obesity pills in the health-tech market, and we don’t think that’s hype. We think it marks a real shift in how weight-loss medicine fits into everyday life. 

OpenAI has acquired health-tech startup Torch, the company said Monday. The acquisition marks an important step in their AI health assistant development. 

Health tech company AbbVie (ABBV) said on Wednesday it plans to build a larger presence in the fast-growing obesity drug market, focusing on treatments designed to be easier for patients.

Nvidia and U.S. drugmaker Eli Lilly said they will spend $1 billion over five years to build a joint AI research lab in the San Francisco Bay Area.

CES 2026 had plenty of flashy ideas, but three products stood out because they point to real changes in the fields of AI, Robotics, and Health tech. 

Health tech company Eli Lilly (LLY) said it will acquire autoimmune drug developer Ventyx Biosciences (VTYX) for $1.2 billion in cash, expanding its research pipeline.

The biggest AI company OpenAI on Wednesday announced the launch of ChatGPT Health, a new experience designed to let users securely connect medical records and wellness apps to its chatbot.

Health tech company Novo Nordisk (NVO) began rolling out the first GLP-1 pill for obesity in the U.S. on Monday. The launch marks the first oral option in a market long dominated by weekly injections.

Elon Musk said his biotech company Neuralink plans to begin high-volume production of its devices in 2026. He also said the company aims to shift to a fully automated surgical procedure in the same year.

Biotech stock Ultragenyx Pharmaceutical Inc (RARE) plunged on Monday after the company said late-stage trials of its bone disease drug failed to meet the main study goal.

Shares of Agios Pharmaceuticals Inc (AGIO) rose nearly 16% on Wednesday after U.S. regulators approved an expanded use of the company’s blood disorder drug.

Cytokinetics Inc. (CYTK) has secured US approval for its first commercial medicine, setting up direct competition with a key heart drug sold by Bristol Myers Squibb Co. (BMY).